



Access this article online

Quick Response Code:



Website:

<https://turkjemergmed.com/>

DOI:

10.4103/tjem.tjem\_49\_25

# Aluminum phosphide: Toxicological profiles, health risks, environmental impact, and management protocols: A review

Selin Çakmakcı Karakaya<sup>1\*</sup>, Cavit Işık Yavuz<sup>2</sup>

<sup>1</sup>Subdivision of Work and Occupational Diseases, Department of Public Health, Faculty of Medicine, Hacettepe University, <sup>2</sup>Subdivision of Environmental Health, Department of Public Health, Faculty of Medicine, Hacettepe University, Ankara, Türkiye

\*Corresponding author

Submitted: 05-02-2025

Revised: 20-03-2025

Accepted: 26-03-2025

Published: 01-07-2025

ORCID:

SÇK: 0000-0003-1098-9628

CİY: 0000-0001-9279-1740

## Address for correspondence:

Dr. Selin Çakmakcı

Karakaya,

Subdivision of Work and

Occupational Diseases,

Department of Public

Health, Hacettepe

NBHD (Mh), A. Adnan

Saygun Street (Cd.),

Hacettepe University

Faculty of Medicine,

Postcode: 06230, Ankara,

Türkiye.

E-mail: selin\_dr91@

hotmail.com

## Abstract:

Aluminum phosphide (AIP) is a common pesticide known for extremely negative environmental, health, and work-related outcomes. Its high availability and easy accessibility have led it to become the chosen method of suicide in many low- and middle-income countries. When AIP reacts with moisture or water, it releases phosphine gas, which is quickly absorbed by the body and leads to severe toxic effects, even death. Occupational and environmental health risks are particularly high in cases of large-scale fumigation or accidental exposure. In Türkiye, two people, one of whom was a child, died due to AIP accidents that affected workplaces and the environment and caused hospitalizations in 2023. In 2024, further suspected cases have been reported, highlighting the ongoing risk. First responders, particularly emergency department team, paramedics, and firefighters, are at significant risk of exposure when managing these cases. The lack of awareness and appropriate protective measures during initial intervention can lead to secondary exposure, worsening the crisis. Medical staff taking care of victims are also at risk of being exposed, further emphasizing the need for stringent safety precautions. Besides, this pollution might cause irreversible damage to soil and water. Thus, this review provides insight into the physical and chemical properties, mechanism of toxicity, current treatment modalities, health–environmental effects, and preventive measures. Given its high toxicity and frequent usage, increased awareness and preparedness among first responders and healthcare professionals are essential. This is a lesson in practice for better safety protocols and emergency response to mitigate health hazards and environmental impacts.

## Keywords:

Aluminum phosphide, environmental effects, health effects, management, occupational health and safety, phosphine, toxicology

## Introduction

Pesticides pose significant risks to human health and the environment, with both suicidal and accidental exposures contributing to major public health challenges. The global incidence of accidental acute pesticide poisoning has surged,

increasing from 25 million cases in 1990 to approximately 385 million cases annually today, resulting in an estimated 11,000 deaths per year.<sup>[1]</sup> Accidental pesticide poisoning impacts nearly 44% of the global farming population. Furthermore, pesticides are frequently used for suicides, particularly in low- and middle-income countries where three-quarters of global suicides occur (mostly Asia).<sup>[2]</sup> This constitutes a critical global public health issue, causing

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Çakmakcı Karakaya S, Yavuz CI. Aluminum phosphide: Toxicological profiles, health risks, environmental impact, and management protocols: A review. Turk J Emerg Med 2025;25:178-90.

at least 110,000–168,000 deaths annually.<sup>[3-5]</sup> Accidental exposure can also result in severe clinical conditions and fatalities.

Among the most widely used pesticides are organophosphates and phosphides, particularly aluminum phosphide (AIP), which is prevalent in low- and middle-income countries. AIP is a common fumigant used to protect stored agricultural products and buildings from pests. It is responsible for approximately 15,000 poisoning cases annually in India, with a mortality rate of 67%.<sup>[6]</sup> Its frequent use in suicides<sup>[7]</sup> highlights the urgent need to address the problems associated with its widespread availability, particularly in developing countries.

### Characteristic Features

AIP is a dark gray or dark yellow, crystalline (sand-like) metal phosphide in solid form.<sup>[8]</sup> It remains stable up to 1832°F (1000°C) but is highly sensitive to moisture. Since the 1940s, AIP has been utilized as a fumigant to protect agricultural products, buildings, and containers from pests and, occasionally, as a rodenticide in nests. It is typically formulated as tablets, pellets, or powder sachets with ammonium compounds to control gas release and prevent flammability.

This formulation is encased in a plastic matrix to regulate moisture exposure and manage gas emission.<sup>[9]</sup> In Türkiye, AIP is widely used against stored-product pests. It is sold in 3-gram tablets containing 56% AIP, which can release 1 g of phosphine (hydrogen phosphide,  $\text{PH}_3$ ) gas when reacting with moisture.<sup>[10]</sup> When AIP pellets react rapidly with water or moisture, they release highly toxic  $\text{PH}_3$  gas, a fumigation agent, along with ammonia and  $\text{CO}_2$ .<sup>[11]</sup> The gas formation rate depends on ambient temperature and humidity.  $\text{PH}_3$  is a low-molecular weight, colorless, highly toxic, and flammable gas released through rapid chemical reactions, allowing deep penetration into materials like grain piles.<sup>[9]</sup> Pure  $\text{PH}_3$  is odorless, but commercial  $\text{PH}_3$  has a garlic or rotting fish odor. However, its odor threshold of 0.15 ppm is not an adequate warning for hazardous concentrations.<sup>[12,13]</sup>

### Paths of phosphine release and regulatory restrictions

Being denser than air,  $\text{PH}_3$  tends to remain near the ground, with dispersion influenced by wind and geography. To mitigate risks, the U.S. EPA recommends notifying individuals within a 250-m radius before application.  $\text{PH}_3$  degrades rapidly in air, water, and soil, with a half-life of 5 h in daylight and 28 h in darkness due to photoreaction,<sup>[14,15]</sup> which results in the formation of nonvolatile phosphorus compounds.<sup>[16]</sup> It does not

bioaccumulate and is unlikely to contaminate crops. As  $\text{PH}_3$  gas is denser than air, it tends to remain near the ground, with dispersion influenced by geography and wind. To mitigate risks, The United States Environmental Protection Agency (U. S. EPA) recommends notifying individuals within a 250-m radius before application.<sup>[17]</sup>

AIP is freely available in some countries and widely used in Central Asia, particularly in India and Iran.<sup>[18]</sup> The European Union regulates AIP under Commission Implementing Regulation (EU) No. 1034/2013, requiring usage by trained professionals, safety measures, and risk mitigation procedures.<sup>[19]</sup> Despite these restrictions, AIP poses risks for misuse, including chemical terrorism.<sup>[20]</sup> AIP poisoning has been extensively reported since the 1980s,<sup>[20]</sup> becoming a leading cause of pesticide-related deaths in India, accounting for 65% of poisoning cases.<sup>[21]</sup> Fatal cases are common in India, Iran, Egypt, Morocco, and Sri Lanka,<sup>[20,22]</sup> but rare in Europe due to sales restrictions.<sup>[23]</sup> In Türkiye, sales are restricted to licensed professionals, minimizing misuse. These restrictions have limited the misuse of AIP for suicide, though fatal accidents have occurred due to illegal use. In May 2023, AIP unloaded at Sapiport Port in Kocaeli ignited for unknown reasons, releasing significant smoke.<sup>[24]</sup> The fire was extinguished after 6 h by emergency response teams. In June 2023, Somali nationals in Ankara used AIP illegally for bedbug control, resulting in two deaths of a mother and a child and 10 hospitalizations.<sup>[25]</sup> In October 2023, an AIP-related explosion occurred at a fumigation company's warehouse in Kocaeli due to water contact. The incident led to the evacuation of 43 individuals, but no fatalities occurred. The workplace had incomplete licensing documentation.<sup>[24]</sup>

### Exposure Limits

The National Institute for Occupational Safety and Health (NIOSH) sets an average exposure limit of 5 mg/m<sup>3</sup> for a 10-h work shift, while the American Conference of Governmental Industrial Hygienists sets it at 5 mg/m<sup>3</sup> for an 8 h.<sup>[26]</sup> Other values include the lowest lethal concentration for AIP (LCLo) (human): 2,800 mg/m<sup>3</sup> (inhalation)<sup>[27]</sup> and the median lethal dose ( $\text{LD}_{50}$ ) (human): 20 mg/kg (inhalation).<sup>[18]</sup>  $\text{PH}_3$  occupational exposure limits are listed in Table 1, with regional variations.<sup>[15]</sup> Long-term exposure to 3 ppm is safe, but 30 min at 500 ppm or brief exposure to 1000 ppm (1400 mg/m<sup>3</sup>) can be lethal.<sup>[28]</sup> Both AIP and  $\text{PH}_3$  are classified as “super toxic” with a probable oral lethal dose below 5 mg/kg. The Turkish regulation sets  $\text{PH}_3$  exposure limits: TWA (time-weighted average measured or calculated for a specified reference period of 8 h) of 0.1 ppm (0.14 mg/m<sup>3</sup>) and STEL (upper exposure

**Table 1: Occupational exposure limit values for phosphine**

	TWA (8 h), ppm (mg/m <sup>3</sup> )	STEL (15 min), ppm (mg/m <sup>3</sup> )
NIOSH REL	0.3 (0.4)*	1 (1)
OSHA PEL	0.3 (0.4)	
ACGIH TLV	0.3	1
NIOSH IDLH	50	

\*10 h. 1 ppm=1.39 mg/m<sup>3</sup>. ACGIH: American Conference of Governmental Industrial Hygienists, IDLH: Immediately dangerous to life or health, NIOSH: National Institute for Occupational Safety and Health, OSHA: Occupational Safety and Health Administration, PEL: Permissible exposure limits, ppm: Parts per million, REL: Recommended exposure limit, STEL: Short-term exposure limit, TLV: Threshold limit value

limit value that should not be exceeded for a period of 15 min) of 0.2 ppm (0.28 mg/m<sup>3</sup>).<sup>[29]</sup>

## Health Effects

Clinical history and findings are critical in suspected ALP poisoning, as routine laboratory tests are unavailable. ALP may be detected in stomach contents or breath using silver nitrate test papers, though this method is rarely employed.<sup>[20]</sup>

### ALP-related toxicity and mechanisms

ALP can irritate the skin, eyes, and mucous membranes.<sup>[8]</sup> ALP is highly toxic when ingested or inhaled, producing PH<sub>3</sub> gas upon reaction with water or acid in the gastrointestinal (GI) tract. PH<sub>3</sub> gas enters systemic circulation, primarily affecting the liver and lungs.<sup>[22]</sup> This mechanism is largely responsible for the toxicity,<sup>[11]</sup> and a fatal outcome can occur quickly depending on the dose.<sup>[20]</sup> PH<sub>3</sub> retention in the lungs causes congestion, hemorrhage, atelectasis, and alveolar damage.<sup>[22,30]</sup> Since ALP is solid under normal conditions, skin and eye poisoning are rare.<sup>[31]</sup> Inhalation of PH<sub>3</sub> gas, formed by moisture on metal phosphides, is another exposure route. PH<sub>3</sub> diffuses systemically and is exhaled, while ALP is primarily excreted in urine as hypophosphite.<sup>[32]</sup>

PH<sub>3</sub> inhibits protein production<sup>[15]</sup> and mitochondrial cytochrome-c oxidase, reducing oxidative phosphorylation by up to 70%.<sup>[33]</sup> PH<sub>3</sub> causes mitochondrial membrane depolarization and generates free radicals, causing lipid peroxidation, protein denaturation,<sup>[34]</sup> and cellular damage, leading to organ dysfunction.<sup>[35]</sup> Organs with high oxygen demand, such as the heart, lungs, kidneys, and liver, are particularly vulnerable.<sup>[36]</sup> In the heart, PH<sub>3</sub> disrupts mitochondria, induces oxidative damage, and alters cell permeability.<sup>[37]</sup> Free oxygen radicals contribute to neutrophil adhesion in coronary arteries and vasoconstriction,<sup>[38]</sup> while tissue hypoperfusion and acidosis may lead to cardiac dysfunction.<sup>[39]</sup> Postmortem findings include myocyte vacuolization and degeneration.<sup>[40]</sup> In addition, PH<sub>3</sub> reacts with hemoglobin, forming Heinz bodies and reducing heme capacity.<sup>[41]</sup>

Liver damage is typically mild, but fatal cases show hepatocyte vacuolization, sinusoidal congestion, and leukocyte clusters.<sup>[42]</sup> While the heart is the primary target, symptoms such as nausea, vomiting, arrhythmias, cyanosis, and pulmonary edema indicate systemic effects on the lungs, GI tract, and kidneys.<sup>[20,22]</sup>

### Acute health effects

Acute ALP exposure effects appear within 10–15 min,<sup>[18,43]</sup> varying by exposure route. Respiratory exposure causes sore throat, cough, headache, dizziness, nausea, and garlic-smelling breath; dermal exposure leads to redness and burning; ocular exposure results in redness and pain; ingestion causes nausea, vomiting, abdominal pain, headache, convulsions, and shock. Symptoms can escalate to cardiovascular collapse, arrhythmia, acute respiratory distress syndrome (ARDS), and neurological issues like coma.

Early signs may include cardiovascular collapse, arrhythmia, ARDS, convulsions, coma, and central nervous system (CNS) depression.<sup>[23]</sup> Less common complications include hemolysis, adrenal insufficiency, pancreatitis, glucose imbalances, methemoglobinemia, hemolytic anemia, disseminated intravascular coagulation, and electrolyte disturbances.<sup>[44]</sup>

Hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.<sup>[45,46]</sup> ALP disrupts endovascular and erythrocyte membranes via free radicals, causing hemolysis and forming methemoglobin (Met-Hb), which reduces oxygen delivery. Met-Hb effects depend on levels: up to 20% alters skin and blood color; over 20% causes neurological and cardiac symptoms; and above 70% is fatal. Rarely, metabolic acidosis triggers severe hemolysis.<sup>[47]</sup>

PH<sub>3</sub> inhalation leads to respiratory irritation, cardiovascular and CNS depression, and severe abdominal pain. Symptoms vary with dose, appearing immediately or within hours.<sup>[9,15]</sup> Cardiovascular complications may cause death within 12–24 h, while liver damage symptoms are delayed by 48–72 h. Deaths after 24 h often result from liver/kidney failure, with pulmonary edema appearing up to 72 h postexposure.<sup>[15]</sup>

Mild poisoning causes fatigue, tinnitus, nausea, chest pressure, and restlessness, resolving in fresh air.<sup>[9]</sup> Severe poisoning may cause extreme fatigue, vomiting, abdominal pain, vertigo, chest pain, and dyspnea. Extremely high concentrations result in severe dyspnea, cyanosis, agitation, ataxia, anoxia, unconsciousness, or death, occurring immediately or days later due to pulmonary edema, respiratory failure,

or brain edema. Dose and exposure type determine severity.<sup>[15,48]</sup>

### *Ocular exposure*

PH<sub>3</sub> has no known ocular or systemic toxicity from eye exposure. Direct contact with liquefied or compressed PH<sub>3</sub> gas may cause frostbite.

### *Ingestion exposure*

PH<sub>3</sub> is gaseous at room temperature, making ingestion unlikely. However, GI exposure to ALP can cause hematemesis, vomiting, and epigastric discomfort. Endoscopic studies show corrosive esophageal and gastric lesions, with possible severe erosions<sup>[23]</sup> and late complications such as esophageal strictures, fistulas, and dysphagia.<sup>[49,50]</sup> If untreated, aspiration may lead to lung infections, causing morbidity or death.<sup>[50]</sup>

### *Inhalation exposure*

#### *Mild-to-moderate exposure*

Symptoms include lung irritation, chest pain, green sputum, dyspnea, and pulmonary edema, alongside cardiovascular issues such as hypotension and arrhythmias. Neurological symptoms such as headache, dizziness, gait disturbances, and diplopia may occur due to brain hypoperfusion. GI symptoms include nausea, vomiting, abdominal pain, and liver damage, accompanied by sweating and cyanosis.<sup>[51]</sup> GI effects include nausea, vomiting, abdominal pain, and liver damage, with general symptoms such as sweating and cyanosis.

#### *Severe exposure*

This may result in pulmonary edema, cardiovascular collapse, ventricular arrhythmias, heart failure, shock, acute hypoxic encephalopathy, seizures, coma, and potentially death.

### *Dermal exposure*

PH<sub>3</sub> gas does not usually cause adverse skin effects or systemic toxicity. Contact with liquefied or compressed PH<sub>3</sub> gas can result in frostbite.

### *Chronic health effects*

While most survivors of acute PH<sub>3</sub> exposure recover without permanent disability, some report damage due to inadequate blood supply to the heart and brain.<sup>[15]</sup> Chronic effects from ALP exposure may appear months or years later, including hepatotoxicity and nephrotoxicity.<sup>[23]</sup>

### *Cancer risk*

The International Agency for Research on Cancer has not classified ALP as carcinogenic.<sup>[52]</sup> While aluminum production is a Group 1 carcinogen, aluminum itself is not classified as carcinogenic. PH<sub>3</sub> remains unclassified for human carcinogenicity (EPA Group D).<sup>[53]</sup>

### *Reproductive system effects*

Current evidence does not indicate adverse effects of ALP or PH<sub>3</sub> gas on human reproduction or development. Some studies suggest no significant impacts.<sup>[54]</sup>

### *Other chronic effects*

Subacute exposure over days may lead to reactive airway dysfunction syndrome months later.<sup>[15]</sup> Repeated exposure may cause bronchitis, with symptoms including cough, sputum production, and breathlessness.<sup>[26]</sup> Aspiration of chemicals can result in pneumonitis or bacterial pneumonia.<sup>[55]</sup> Liver damage may lead to jaundice, proteinuria, and renal failure.<sup>[15]</sup>

### *Health effects of chronic and repeated exposure*

Although PH<sub>3</sub> is classified under Group D for carcinogenicity, chronic exposure has been linked to chromosomal damage.<sup>[15]</sup> Chronic exposure to very low concentrations can cause anemia, bronchitis, GI disorders, kidney failure, vision, speech, and motor disorders. These adverse health effects may be of greater concern for children exposed to similar levels. Toothache, jaw swelling, and spontaneous breaking of bones (Phossy jaw) are also consequences of chronic exposure.<sup>[56]</sup>

## *Diagnostic and Adjunctive Tests*

Accurate diagnosis of ALP poisoning relies on clinical suspicion, thorough patient history, and crime scene investigation, coupled with timely communication with healthcare facilities. Although limited chemical and analytical tests exist, they are not routine in emergency settings. The silver nitrate test serves as a simple spot test for detecting PH<sub>3</sub> gas in gastric fluid or breath.<sup>[57]</sup> Ammonium molybdate testing is another option for stomach contents, offering both qualitative and quantitative results.<sup>[58]</sup> Gas chromatography is the most sensitive method for detecting PH<sub>3</sub> in blood or air.<sup>[59]</sup> Key tools:

- **Electrocardiogram (ECG):** This may show sinus tachycardia, ST segment abnormalities, inverted T waves, myocardial infarction, atrioventricular block (particularly right bundle branch), or complete heart block. ECG typically normalizes within 10–25 days if the patient survives the initial 24 h
- **Chest X-ray:** Pulmonary edema and pleural effusion
- **Blood sugar monitoring:** This may indicate hypoglycemia
- **Arterial blood gas (ABG)/venous blood gas analysis:** This can reveal metabolic acidosis, methemoglobinemia, or both, often accompanied by respiratory alkalosis
- **Liver and kidney function tests:** Crucial for diagnosing



AIP poisoning.<sup>[32,60]</sup> Elevated serum aspartate and alanine aminotransferase levels are common in cases of liver involvement<sup>[61]</sup>

- Serum electrolytes: This may show imbalances
- Blood tests: Leukopenia, anemia, or intravascular hemolysis
- Cardiac markers: Creatine phosphokinase (CK), CK-myocardial band (MB), troponin-T (TnT), and troponin-I (TnI) can identify myocardial damage.<sup>[62,63]</sup>

For individuals with occupational exposure, annual pulmonary function tests, as well as liver and kidney function tests, are recommended. Chest X-rays should be performed if symptoms develop, or overexposure occurs.<sup>[26]</sup> A comprehensive history and physical examination are essential in workplace evaluations.

## Differential Diagnosis

The clinical presentation of AIP poisoning may mimic infectious, inflammatory, or metabolic conditions, potentially delaying diagnosis and treatment. Mild cases may resemble upper respiratory infections, while severe cases could be confused with other pesticide poisonings, acute coronary syndrome, myocarditis, cardiopulmonary edema, pneumonia, or ARDS.<sup>[64]</sup> Zinc phosphide poisoning presents with similar symptoms but tends to progress more slowly and has a lower mortality rate.<sup>[65,66]</sup>

## Treatment Methods

### First aid

Initial interventions should be performed on-site.<sup>[26,43]</sup> The local poison information center should be contacted for guidance. Victims should move to fresh air immediately, as mild symptoms may subside there, though first aid must continue until professional help arrives.<sup>[9]</sup> Medical help should be requested immediately by calling appropriate emergency services or be referred to the hospital.

### Ocular contact

Rinse eyes with water for at least 15 min, lifting eyelids. Remove contact lenses if possible.

### Dermal contact

Wear gloves, remove contaminated clothing, and wash skin with soap and water.

### Respiratory contact

Move the victim to fresh air and rest in an upright position. Avoid mouth-to-mouth resuscitation; use rescue breathing if needed. Perform cardiopulmonary resuscitation if necessary.

### Oral contact

Rinse mouth and avoid inducing vomiting.

### Treatment

Treatment should begin immediately after taking a brief history and conducting a clinical examination, without waiting for a confirmed diagnosis. Healthcare personnel should wear full-face masks and latex gloves, as small-pore masks without canisters do not protect against  $\text{PH}_3$  exposure (see respiratory protection).

### Patient stabilization

#### Airway and breathing

If the patient is conscious and responds normally, the airway is likely open.<sup>[67]</sup> Untreated airway spasms or obstructions can quickly lead to arrest, so obstructions should be cleared by suctioning. Ventilation support may be required if breathing is inadequate, using a bag valve mask operated by trained personnel.

### Circulation

Monitor capillary refill time, pulse, and skin color for signs of poor circulation, such as sweating and confusion. If a stethoscope is available, heart auscultation should be performed. Check blood pressure and ECG signals if possible. In cases of hypotension, lay the patient flat with legs slightly raised, secure IV access, and begin supportive fluid therapy, following guidelines.<sup>[67]</sup>

### Decontamination

#### Gastric lavage

Early gastric lavage (GL) with potassium permanganate (1:10,000), which oxidizes  $\text{PH}_3$  to nontoxic phosphate,<sup>[68]</sup> or a combination of coconut oil and sodium bicarbonate, is recommended.<sup>[20,22,23]</sup> However, potassium permanganate may cause hemolysis and methemoglobinemia in some patients.<sup>[47]</sup>

Paraffin oil (50 ml) can create a protective barrier that reduces  $\text{PH}_3$  absorption, decreasing gastric symptoms and complications, and its effectiveness, along with sodium bicarbonate, was demonstrated in a recent randomized controlled trial, showing significant reductions in gastric symptoms and complications.<sup>[69]</sup> A meta-analysis showed paraffin oil reduced mortality risk by 41%, intubation by 41%, and vasopressor need by 29%, with similar benefits observed for coconut oil.<sup>[70]</sup>

For oral solid phosphide ingestion, GL with activated charcoal is suggested, though some argue it may be ineffective due to AIP's molecular weight being below the absorption limit of activated charcoal.<sup>[71]</sup> Water-based treatments are not recommended for gastric decontamination.<sup>[72]</sup>

## Elimination

### Coconut oil

Coconut oil may block the systemic absorption of  $\text{PH}_3$  by coating the stomach wall.<sup>[73]</sup> In a study, GI lavage with diluted potassium permanganate, coconut oil, and sodium bicarbonate was used on seven patients with severe hemodynamic instability, with four patients surviving, suggesting coconut oil's potential effectiveness in the absence of a specific antidote.<sup>[74]</sup>

### Antioxidants

Due to the oxidative effects of  $\text{PH}_3$  toxicity, antioxidants like IV magnesium sulfate and N-acetylcysteine (NAC) are recommended.<sup>[22,23]</sup> A meta-analysis on acute AIP poisoning showed NAC reduced mortality by 50% and decreased mechanical ventilation needs, though not significantly.<sup>[75]</sup>

Other antioxidants, such as Vitamins C, E, and NAC, also showed efficacy in case reports and clinical trials.<sup>[76]</sup> In a randomized controlled study, 36 AIP-poisoned patients receiving 400 mg IM Vitamin E twice daily showed significantly reduced mechanical ventilation need (30% vs. 62%) and mortality rate (15% vs. 50%) compared to controls.<sup>[77]</sup> Melatonin may counteract AIP-induced cardiotoxicity by reducing mitochondrial damage and apoptosis through limiting mitochondrial permeability, impairing caspase activation and inhibiting cytochrome-c release.<sup>[78]</sup> Coenzyme Q10 (CoQ10) has shown promise in reducing oxidative stress, enhancing mitochondrial function, and protecting liver cells in AIP toxicity cases.<sup>[79]</sup> Resveratrol<sup>[80]</sup> and cerium oxide ( $\text{CeO}_2$ ) nanoparticles<sup>[81]</sup> demonstrated protective effects in cardiac myocyte cells by reducing oxidative stress and apoptosis, indicating potential therapeutic value for AIP cardiotoxicity. Injecting healthy mitochondria in AIP-exposed rats improved survival rates and reduced oxidative damage, suggesting mitochondrial transplantation as a potential treatment.<sup>[82]</sup> At concentrations of 125 and 250  $\mu\text{g}/\text{kg}$ , the survival rates were boosted to 40% and 56.25%, respectively, over 30 days.

### Lipid sink theory

Since  $\text{PH}_3$  may also have fat-soluble properties, IV lipid emulsion therapy, based on the lipid sink theory,<sup>[83]</sup> showed clinical and biochemical benefits in AIP poisoning by improving survival time, blood pressure, and metabolic acidosis, though mortality impact remains unclear.<sup>[84]</sup> The study indicated positive trends such as a decreased need for intubation and mechanical ventilation in the intervention groups.

### Symptomatic and supportive treatment approaches

Since there is no specific treatment for AIP poisoning,

symptomatic and supportive care are essential, with timing significantly impacting prognosis. Mild cases may require rest and warmth, while severe cases often need intensive care unit (ICU) monitoring.<sup>[9]</sup>

Mortality rates range from 30% to 100%, depending on dosage.<sup>[23]</sup> Although the survival rate is generally very low for poisonings of  $\geq 1500$  mg, few patients survive as a result of poisonings of  $\geq 9000$  mg.<sup>[20,85]</sup> Early emesis and supportive therapy have improved survival in some cases of high-dose poisoning.<sup>[20]</sup>

For complications, standard therapy for seizure, blood transfusions, antibiotics for aspiration pneumonia, and hydrocortisone for adrenal insufficiency may be needed. A 17-year-old girl who ingested 6 g of AIP for suicide, despite AIP doses of 150–500 mg having high mortality rates, survived severe symptoms including metabolic acidosis and shock with hydrocortisone infusion treatment.<sup>[60]</sup> A 40-year-old male who accidentally ingested 3 g of AIP received IV fluids and intermittent dialysis, which eliminated the need for norepinephrine, and was later extubated and discharged.<sup>[86]</sup> Patients should be closely monitored for arrhythmias, acidosis, shock, and ARDS, with prompt intervention as these conditions arise. Mortality is primarily due to arrhythmias within the first 24 h and to acidosis, shock, and ARDS thereafter.

Symptomatic patients should receive oxygen for shortness of breath, with 72-h monitoring and chest examinations. Hypoxia may be managed with oxygen, early positive pressure ventilation, or intubation to minimize pulmonary edema.<sup>[87]</sup> In a rare case, hyperbaric oxygen therapy led to recovery from AIP poisoning, though further research is needed.<sup>[88]</sup> Aerosol bronchodilators are recommended for acute bronchospasm, with consideration for myocardial health.<sup>[32,89,90]</sup>

In cases of toxic myocarditis with cardiogenic shock, one patient survived with an intra-aortic balloon pump after resistance to IV fluids and inotropic treatments.<sup>[89,90]</sup> Another 19-year-old patient with severe lactic acidosis and cardiac dysfunction was successfully treated with extracorporeal membrane oxygenation, though this complex treatment is reserved for high-risk cases.<sup>[91]</sup> Continuous renal replacement therapy was effective in two patients with shock, while hemodialysis proved beneficial for renal failure and severe acidosis, despite limited  $\text{PH}_3$  removal.<sup>[20,92]</sup>

A recent systematic review evaluating the role of exogenous insulin euglycemia therapy in symptomatic AIP poisoning found that insulin administration reduced mortality, required lower vasopressor doses, and

decreased the need for intubation.<sup>[93]</sup> In addition, it was associated with improved systolic blood pressure (SBP) and favorable biochemical changes (e.g., increased bicarbonate and decreased lactate levels), making it a safer alternative to vasopressor-only treatment. Hypoglycemia, hyperglycemia, and hypokalemia were the most frequently reported adverse events, but they were generally manageable. Despite variability in insulin regimens across studies, findings consistently demonstrated hemodynamic stabilization and improved survival in ALP poisoning. An initial bolus of 1 IU/kg, followed by infusion rates of 0.2–0.5 IU/kg/h, was linked to faster blood pressure stabilization, whereas lower bolus doses (0.1–0.2 IU/kg) required longer infusion durations to achieve similar effects. In refractory hypotension cases (SBP <90 mmHg), dose escalation up to 3 IU/kg/h further improved circulatory function, while higher doses (up to 10 IU/kg) correlated with progressive SBP increases, reinforcing a dose-dependent response. Prolonged insulin infusion was also associated with reduced mortality, with each additional hour of therapy showing incremental survival benefits.

The pathophysiological basis for insulin's benefit in ALP poisoning lies in its ability to counteract mitochondrial dysfunction and metabolic failure.  $\text{PH}_3$  gas inhibits cytochrome c oxidase, leading to oxidative phosphorylation failure, metabolic starvation, and severe refractory hypotension, which is the primary cause of mortality. The myocardium is particularly vulnerable, experiencing cell membrane dysfunction, oxidative stress, and impaired glucose utilization, exacerbating circulatory collapse. Insulin, a key regulator of cardiac metabolism, shifts myocardial energy utilization from  $\beta$ -oxidation to glycolysis, thereby enhancing cardiac contractility and tissue perfusion. Given its established role in conditions such as beta-blocker and calcium channel blocker toxicity, diabetic ketoacidosis, and metabolic crises, insulin euglycemia therapy has emerged as a promising adjunct in ALP poisoning management. With current knowledge, exogenous insulin appears beneficial in ALP poisoning. However, high-quality randomized controlled trials are still needed to establish standardized protocols and confirm its clinical efficacy with confidence.

In a study evaluating the effect of Glucose-Insulin-Potassium (GIK) infusion therapy on ALP poisoning, 20% of 15 ALP poisoning cases treated with GIK resulted in death, while 80% survived.<sup>[94]</sup> When compared with previous case results, it was stated that GIK treatment provided hemodynamic stabilization and allowed patients to be followed up for a longer period. It was observed that patients transferred to acute unit survived for a longer period. Normally, low blood pressure is a

poor prognostic factor in ALP poisoning, but here it can be considered that GIK may help stabilize hypotension. Nevertheless, GIK treatment cannot be considered a completely rescue treatment but can be used within the scope of supportive treatment.

Dihydroxyacetone was tested on 76 ALP poisoning patients, with a survival rate of 65.5% in the dihydroxyacetone group versus 33.3% in the control group.<sup>[95]</sup> Dihydroxyacetone improved biomarkers without significant adverse effects, suggesting its potential as an effective adjunct therapy.

Sobh *et al.* analyzed acute ALP poisoning management among Egyptian physicians, revealing significant variability in approaches.<sup>[96]</sup> Noradrenaline was used by 90.7% without standard dosing; 84.1% employed oil (primarily paraffin oil) for GI decontamination, with sodium bicarbonate, proton pump inhibitors, IV magnesium sulfate, and antioxidants also commonly used. Using oil improved outcomes by 4.62 times. Clinical toxicologists achieved higher success rates, often employing oil and magnesium sulfate. The study highlights inconsistent treatment protocols and suggests that toxicologists' methods may significantly improve outcomes.

### Additional recommendations post-intervention

The affected person should avoid work, especially fumigation tasks, for 48 h to allow for toxin elimination.<sup>[9]</sup> Complete abstinence from alcohol is also strongly advised after poisoning.

## Prognostic Factors

Dose is a key predictor of outcome. The lethal dose of ALP is 150–500 mg, with mortality rates between 70% and 100%.<sup>[60]</sup> Mortality in adults rises to 30%–100% with ALP intake of 500 mg or more,<sup>[23]</sup> and survival decreases with higher doses. Non-survivors show lower ABG levels and poor treatment response.

In Ethiopia, 26% of poisonings were due to metal phosphides, mainly ALP, causing 55% of deaths.<sup>[97]</sup> ALP poisoning often leads to ICU admission and mechanical ventilation, reflecting its high fatality rate.

Saleh *et al.* reported that hypotension, cardiogenic shock, and palpitations were the most common symptoms in 60 ALP patients, with a mortality rate of 92%.<sup>[98]</sup> Poor prognosis is associated with cardiogenic shock, arrhythmias, and metabolic acidosis.

In Egypt, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels ( $\geq 72$  pg/ml) predicted mortality in ALP poisoning cases, whereas TnI and CK-MB

did not.<sup>[99]</sup> These findings suggest that NT-proBNP could serve as an early marker of poor prognosis in AIP poisoning cases.

Higher blood  $\text{PH}_3$  levels correlate with higher mortality; levels  $\leq 1.067$  mg suggest survival.<sup>[100]</sup> Swallowing small amounts, expired tablets,<sup>[101]</sup> or early supportive care can improve survival.<sup>[20]</sup>

Mehrpour *et al.* identified factors associated with poor prognosis in AIP poisoning, including hyperglycemia, high simplified acute physiology score (SAPS II) and acute physiology and chronic health evaluation (APACHE II) scores, hypotension, acidosis, low prothrombin rate, leukocytosis, methemoglobinemia, hyperuricemia, ECG abnormalities, low Glasgow coma scale, acute kidney failure, use of vasoactive drugs, the absence of postingestion vomiting, and mechanical ventilation need.<sup>[23]</sup>

A case report described a unique instance of AIP toxicity in a 30-year-old male with G-6-PD deficiency, suggesting a protective effect against severe AIP complications.<sup>[102]</sup> The patient, who showed jaundice and anemia, recovered with supportive care, indicating G-6-PD deficiency may help counteract oxidative damage in AIP poisoning.

Smoking and alcohol intake may exacerbate health issues caused by AIP, as smoking increases risks for respiratory and cardiovascular diseases, and excessive alcohol can damage the liver.<sup>[26]</sup> Quitting smoking and consulting a doctor before taking phosphorus supplements are recommended for risk reduction. Given that more than moderate alcohol consumption can cause liver damage, alcohol intake could exacerbate the liver damage caused by AIP.

A study with 94 acute AIP poisoning cases found that high shock index (SI) and modified SI (MSI) were significantly linked to ICU admission and mortality.<sup>[103]</sup> SI and MSI correlated with poisoning severity and predicted ICU admission and mortality at cutoffs  $> 1.14$  and  $> 1.47/1.5$ , respectively, proving their usefulness in assessing AIP poisoning severity.

## Environmental and Ecological Impacts

AIP is unstable in most environments, decomposing upon contact with atmospheric moisture or soil into aluminum hydroxide and  $\text{PH}_3$ , the toxic substances in these pesticides.<sup>[17]</sup> Aluminum hydroxide residues can form natural mineral phases, while  $\text{PH}_3$  oxidizes into inorganic phosphates and other phosphorus oxyacids.  $\text{PH}_3$  below the soil surface is rapidly adsorbed and degraded, with interaction types varying by soil.<sup>[104-106]</sup> The risk of water contamination is low, as  $\text{PH}_3$  degrades within days.<sup>[17]</sup>  $\text{PH}_3$  near the soil surface diffuses into the

atmosphere for photodegradation, while subsurface  $\text{PH}_3$  binds to soil and oxidizes to phosphates.

AIP is generally considered low risk to nontarget organisms and water bodies, except for endangered species exposed to these chemicals in their habitats. Label restrictions, environmental fate, and aquatic toxicity data indicate minimal risk to aquatic species, habitats, and terrestrial plants.<sup>[107]</sup> However, AIP poses high risks to burrowing terrestrial vertebrates and invertebrates exposed to phosphine gas during treatment. Applicators can minimize risks by inspecting nests and ensuring the presence of target animals before application. There is no secondary risk to nontarget species, as  $\text{PH}_3$  dissipates quickly and does not accumulate in target animals. Labels include restrictions to limit exposure and risks to nontarget terrestrial species.

## Decontamination

Decontamination aims to safely and effectively remove toxic substances, ensuring safety for individuals and equipment. Care is needed, as absorbed agents may release as gases from clothing and skin.<sup>[15]</sup>

### Decontamination corridor

Recommendations for first responders include:

- Position the decontamination corridor upwind and uphill of the hot zone. Establish two corridors: One for entering and another for exiting the hot zone to the cold zone. Ensure the exit zone is also upwind and uphill
- Workers in the decontamination area must wear appropriate personal protective equipment (PPE). Provide a detergent-water solution ( $8 < \text{pH} < 10.5$ ) for decontamination, along with soft brushes to clean PPE. Use durable, labeled polyethylene bags for disposing of contaminated PPE.

### Individual decontamination

Effective methods for individual decontamination include:

#### Decontamination of the first aid team

- Wash the PPE of the first aid team with soap and water using a soft brush, moving downward (head to toe), ensuring all areas, including clothing folds, are cleaned. Rinse with cold or lukewarm water until contaminants are removed
- Remove PPE by rolling it down from top to bottom (head to toe) without pulling it over the head. Remove the self-contained breathing apparatus last
- Place all PPE in durable, labeled polyethylene bags.

#### Decontamination of patient(s)

- Move patients to the decontamination corridor from the contaminated area



- Undress patients (at least to their underwear) and place their belongings in labeled polyethylene bags
- Wash the patient's skin with soap and cold or lukewarm water, taking care not to damage the skin. Cover any wounds before decontamination
- Protect patients from shock and heat loss by covering them
- Transfer patients to an area for emergency medical treatment.

### Environmental decontamination

Guidelines for environmental or spill decontamination:

- Avoid contact with or walking through the spill; wear appropriate PPE if necessary
- Keep flammable materials (e.g., wood, paper, and oil) away from the spill. Use water spray to reduce or direct vapors but avoid contact between water and the spilled substance
- Prevent water from reaching the spill or leak source
- If safe, stop the leak and position leaking containers to release gas instead of liquid
- Block entry into waterways, sewers, basements, or confined spaces
- Isolate and ventilate the area until the gas dissipates.

### Prevention Methods

To reduce risks from toxic substances:

1. Minimize exposure: Use safer alternatives where possible.
2. Environmental controls: Ensure adequate ventilation in enclosed spaces.
3. Personal protection: Proper PPE (respirators, gloves, and protective clothing) should be used when handling phosphine-releasing compounds.
4. Emergency preparedness: Training for healthcare providers and first responders on early recognition, decontamination, and treatment protocols for AIP poisoning.
5. Regulation and education: Restrict access to hazardous pesticides and ensure awareness among agricultural and industrial workers.

### General precautions

The use of highly toxic substances should be minimized whenever possible. If exposure is unavoidable, strict adherence to safety guidelines is essential. Key precautions include:<sup>[9,26]</sup>

1. Ensure proper ventilation in enclosed spaces where phosphine gas may accumulate
2. Use appropriate protective equipment (e.g., gloves, respirators, and protective clothing) when handling AIP
3. Avoid direct contact – wear gloves when handling AIP tablets or pellets
4. Do not rely on odor detection – use gas monitoring devices to confirm phosphine levels

5. Prevent ingestion or inhalation – prohibit smoking, eating, or drinking in areas where AIP is used
6. Emergency preparedness – ensure respiratory protection is available in case of unexpected gas exposure
7. Immediate decontamination – wash exposed skin immediately and at the end of the work shift
8. Post warning signs – inform all personnel and bystanders of fumigation activities
9. Avoid residual exposure – ensure thorough ventilation after fumigation or grain turnover before re-entry.

### Workplace controls and practices

Engineering controls are the most effective way to reduce exposure to hazardous substances like AIP. Whenever possible, a less toxic alternative should be used. Key safety measures include:<sup>[26]</sup> ventilation and containment (ensure local exhaust ventilation in enclosed spaces where phosphine gas may accumulate), isolation (restrict access to areas where AIP is used and implement enclosed handling processes to limit exposure), protective measures (while engineering controls are preferable, respiratory masks and PPE should be used in high-risk situations), and exposure assessment (employers must evaluate substance toxicity, emission levels in the workplace, risk of skin, or ocular exposure).

AIP should be transferred via automated systems when possible. Before entering a potentially contaminated area, gas concentration levels must be checked to prevent explosive conditions.

Good work practices for exposure reduction include:<sup>[26]</sup>

1. Change contaminated clothing immediately to prevent secondary exposure
2. Do not bring work clothes home – they should be cleaned by trained personnel
3. Provide emergency decontamination facilities, including eyewash stations and safety showers
4. Immediately wash exposed skin to remove any residual chemical
5. Strict hygiene policies: Prohibit eating, drinking, or smoking in areas where AIP is handled
6. Minimize dust exposure by using vacuum cleaners instead of dry sweeping.

### Personal protective equipment

While workplace controls are the primary means of exposure prevention, PPE is essential in high-risk scenarios, such as outdoor applications, confined spaces, or emergency response situations.<sup>[26]</sup> The Occupational Safety and Health Administration (OSHA) recommends that employers assess exposure risks, select appropriate PPE, and ensure proper training on usage and limitations.<sup>[108]</sup>

### Clothing

- Minimize skin contact with AIP by wearing protective gloves and clothing
- Ensure protective suits, gloves, footwear, and headgear are clean and readily available before handling PH<sub>3</sub>.

### Eye protection

- Use goggles or face shields when handling AIP powders or in high-risk exposure areas.

### Respiratory protection

- Proper respiratory protection is essential in high-exposure scenarios to PH<sub>3</sub>. Emergency responders should follow these guidelines
- Use NIOSH-/OSHA-approved respirators, selecting appropriate models based on exposure levels and emergency response needs<sup>[48]</sup>
- Air-supplied or self-contained breathing apparatus (SCBA) is required for high-risk situations
- Respiratory protection guidelines based on PH<sub>3</sub> exposure.<sup>[48]</sup>

Up to 3 ppm:

- Any air-supplied respirator.

Up to 7.5 ppm:

- Air-supplied respirator in continuous flow mode.

Up to 15 ppm:

- Chin-style air-purifying respirator with canisters for PH<sub>3</sub> and a full-face mask
- Self-contained breathing apparatus with a full-face mask
- Supplied air respirator with full-face protection.

Up to 50 ppm:

- Supplied-air respirator operating in pressure-demand or positive-pressure mode.

Emergency or immediately dangerous to life or health conditions:

- Self-contained breathing apparatus with a full-face mask operating in pressure-demand or positive-pressure mode
- Supplied air respirator with full-face protection and an auxiliary positive-pressure device.

## Conclusion

Acute AIP poisoning remains a significant global health and environmental challenge. Advances in understanding its toxicity and clinical effects have improved management, but a specific antidote is still unavailable. Various treatment approaches require further validation. Preventive measures, such as

restricting access to phosphide compounds, banning their use as pesticides, and educating healthcare professionals on early recognition and management of phosphide poisoning, are essential to mitigate human poisoning risks.

### Authors' contributions

SÇK developed the concept, conducted the literature search, created the table, and wrote and reviewed the manuscript. CIY contributed to the concept, performed the literature search, edited and reviewed the manuscript, and provided appropriate advice on the content of the paper. Both authors contributed to writing the manuscript and read and approved the final version.

### Conflicts of interest

None declared.

### Funding

None.

## References

1. Boedeker W, Watts M, Clausing P, Marquez E. The global distribution of acute unintentional pesticide poisoning: Estimations based on a systematic review. *BMC Public Health* 2020;20:1875.
2. World Health Organization. Suicide; 2023. Available from: <https://www.who.int/news-room/fact-sheets/detail/suicide>. [Last accessed on 2024 Oct 07].
3. Eddleston M. Patterns and problems of deliberate self-poisoning in the developing world. *QJM* 2000;93:715-31.
4. Jeyaratnam J. Acute pesticide poisoning: A major global health problem. *World Health Stat Q* 1990;43:139-44.
5. Mew EJ, Padmanathan P, Konradsen F, Eddleston M, Chang SS, Phillips MR, *et al.* The global burden of fatal self-poisoning with pesticides 2006-15: Systematic review. *J Affect Disord* 2017;219:93-104.
6. Navabi SM, Navabi J, Aghaei A, Shaahmadi Z, Heydari R. Mortality from aluminum phosphide poisoning in Kermanshah province, Iran: Characteristics and predictive factors. *Epidemiol Health* 2018;40:e2018022.
7. Sarkar MK, Ghosh N, Rakesh U, Prasad R, Raj R. Acute aluminium phosphide poisoning: A case report of rare survival with cardiac, metabolic, hepatic, and renal complications. *J Family Med Prim Care* 2022;11:7452-5.
8. National Center for Biotechnology Information. PubChem Compound Summary for CID 30332, Aluminum Phosphide; 2023. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Aluminum-phosphide>. [Last accessed on 2024 Aug 15].
9. Bond EJ. Phosphine. *Manual of Fumigation for Insect Control*; 1984. Available from: <https://www.fao.org/3/X5042E/x5042E0a.htm#Phosphine>. [Last accessed on 2024 Aug 11].
10. European Chemicals Agency (ECHA). Aluminium Phosphide Releasing Phosphine (PT 14) Assessment Report; 2008. Available from: <https://echa.europa.eu/documents/10162/4b618b92-38eb-ad10-f678-8a667a212e32>. [Last accessed on 2023 Aug 16].
11. Anger F, Paysant F, Brousse F, Le Normand I, Develay P, Gaillard Y, *et al.* Fatal aluminum phosphide poisoning. *J Anal Toxicol* 2000;24:90-2.
12. Bond EJ, Dumas T. Loss of warning odour from phosphine. *J Stored Prod Res* 1967;3:389-92.
13. Dumas T, Bond EJ. Separation of phosphine from odour-producing impurities. *J Stored Prod Res* 1974;10:67-8.
14. Agency for Toxic Substances and Disease Registry. Phosphine;

2002. Available from: <https://www.atsdr.cdc.gov/toxfaqs/tfaqs177.pdf>. [Last accessed on 2024 Aug 11].
15. The National Institute for Occupational Safety and Health (NIOSH). Phosphine: Lung Damaging Agent; 2011. Available from: [https://www.cdc.gov/niosh/ershdb/emergencyresponsecard\\_29750035.html](https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750035.html). [Last accessed on 2023 Aug 11].
16. World Health Organization. Phosphine and Selected Metal Phosphides; 1988. Available from: <https://apps.who.int/iris/handle/10665/37212>. [Last accessed on 2024 Sep 15].
17. United States Environmental Protection Agency (U.S. EPA). Prevention, Pesticides and Toxic Substances- R.E.D. FACTS- Aluminum and Magnesium Phosphide; 1998. Available from: [https://www3.epa.gov/pesticides/chem\\_search/reg\\_actions/reregistration/fs\\_PC-066501\\_1-Dec-98.pdf](https://www3.epa.gov/pesticides/chem_search/reg_actions/reregistration/fs_PC-066501_1-Dec-98.pdf). [Last accessed on 2024 Jul 15].
18. Moghadamnia AA. An update on toxicology of aluminum phosphide. *Daru* 2012;20:25.
19. Food and Agriculture Organization of the United Nations (FAO). Commission Implementing Regulation (EU) No. 1034/2013 Approving Aluminium Phosphide Releasing Phosphine as an Active Substance for Use in Biocidal Products for Product Type 20. Official Journal of the European Union; 2013. Available from: <https://faolex.fao.org/docs/pdf/eur128299.pdf>. [Last accessed on 2023 Oct 03].
20. Gurjar M, Baronia AK, Azim A, Sharma K. Managing aluminum phosphide poisonings. *J Emerg Trauma Shock* 2011;4:378-84.
21. Singh D, Jit I, Tyagi S. Changing trends in acute poisoning in Chandigarh zone: A 25-year autopsy experience from a tertiary care hospital in Northern India. *Am J Forensic Med Pathol* 1999;20:203-10.
22. Bogle RG, Theron P, Brooks P, Dargan PI, Redhead J. Aluminium phosphide poisoning. *Emerg Med J* 2006;23:e3.
23. Mehrpour O, Jafarzadeh M, Abdollahi M. A systematic review of aluminium phosphide poisoning. *Arh Hig Rada Toksikol* 2012;63:61-73.
24. Çakmakcı Karakaya S, Yavuz CI. Hidden lethal hazard: Aluminum phosphide incidents in Türkiye. *Thorac Res Pract* 2024;25:221-2.
25. Cumhuriyet Gazetesi. Breaking News: Pesticide Tragedy in Ankara: 2 Dead, 10 Injured, 1 in Critical Condition; 2023. Available from: <https://www.cumhuriyet.com.tr/turkiye/son-dakika-ankarada-tarim-ilaci-faciayi-2-olu-1i-agir-10-yarali-2091164>. [Last accessed on 2023 Aug 14].
26. New Jersey Department of Health and Senior Services. Hazardous Substance Fact Sheet-Aluminum Phosphide; 2005. Available from: <https://www.nj.gov/health/eoh/rtkweb/documents/fs/0063.pdf>. [Last accessed on 2024 Jul 13].
27. Haz-Map. Aluminum Phosphide; 2023. Available from: [https://haz-map.com/Agents/1503?referer=Search&refer\\_data\[s\]=aluminum+phosphide&return\\_url=%2fSearch%3fdofilter%3d1%26f%255Btab%255D%3dtab1%26f%255Bs%255D%3daluminum%2bphosphide](https://haz-map.com/Agents/1503?referer=Search&refer_data[s]=aluminum+phosphide&return_url=%2fSearch%3fdofilter%3d1%26f%255Btab%255D%3dtab1%26f%255Bs%255D%3daluminum%2bphosphide). [Last accessed on 2024 Aug 10].
28. Spencer EY. Guide to the Chemicals Used in Crop Protection. 7<sup>th</sup> ed., Vol. 1093. Ottawa, Canada: Research Institute, Agriculture Canada, Information Canada; 1982.
29. Republic of Türkiye Ministry of Labor and Social Security. Regulation on Health and Safety Precautions in Working with Chemical Substances; 2013. Available from: <https://www.resmigazete.gov.tr/eskiler/2013/08/20130812-1.htm>. [Last accessed on 2023 Aug 10].
30. Rahbar Taromsari M, Teymourpour P, Jahanbakhsh R. Survey the histopathological findings in autopsy of poisoned patients with rice tablet (aluminium phosphide). *J Guilan Univ Med Sci* 2011;19:56-63. Available from: <https://journal.gums.ac.ir/article-1-171-en.html>. [Last accessed on 2023 Aug 19].
31. Karimani A, Mohammadpour AH, Zirak MR, Rezaee R, Megarbane B, Tsatsakis A, *et al.* Antidotes for aluminum phosphide poisoning – An update. *Toxicol Rep* 2018;5:1053-9.
32. Hashemi-Domeneh B, Zamani N, Hassanian-Moghaddam H, Rahimi M, Shadnia S, Erfantalab P, *et al.* A review of aluminium phosphide poisoning and a flowchart to treat it. *Arch Ind Hyg Toxicol*. 2016;67:183-93.
33. Singh S, Bhalla A, Verma SK, Kaur A, Gill K. Cytochrome-c oxidase inhibition in 26 aluminum phosphide poisoned patients. *Clin Toxicol (Phila)* 2006;44:155-8.
34. Hsu CH, Quistad GB, Casida JE. Phosphine-induced oxidative stress in hepa 1c1c7 cells. *Toxicol Sci* 1998;46:204-10.
35. National Center for Biotechnology Information. PubChem Compound Summary for CID 30332, Phosphine; 2024. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Phosphine>. [Last accessed on 2024 Oct 09].
36. Moazezi Z, Abedi SH. A successful management of aluminum phosphide intoxication. *Caspian J Intern Med* 2011;2:286-8.
37. Anand R, Binukumar BK, Gill KD. Aluminium phosphide poisoning: An unsolved riddle. *J Appl Toxicol* 2011;31:499-505.
38. Gouda AS, El-Nabarawy NA, Ibrahim SF. *Moringa oleifera* extract (Lam) attenuates aluminium phosphide-induced acute cardiac toxicity in rats. *Toxicol Rep* 2018;5:209-12.
39. Marashi SM. A new concept against the priority of vasoactive agents in the management of severe hypotension associated with aluminum phosphide poisoning. *Eur Rev Med Pharmacol Sci* 2016;20:3517-8.
40. Shah V, Baxi S, Vyas T. Severe myocardial depression in a patient with aluminium phosphide poisoning: A clinical, electrocardiographical and histopathological correlation. *Indian J Crit Care Med* 2009;13:41-3.
41. Shadnia S, Soltaninejad K, Hassanian-Moghadam H, Sadeghi A, Rahimzadeh H, Zamani N, *et al.* Methemoglobinemia in aluminum phosphide poisoning. *Hum Exp Toxicol* 2011;30:250-3.
42. Saleki S, Ardalan FA, Javidan-Nejad A. Liver histopathology of fatal phosphine poisoning. *Forensic Sci Int* 2007;166:190-3.
43. International Labour Organization (ILO). International Chemical Safety Cards (ICSCs)-Aluminum Phosphide; 2018. Available from: [https://www.ilo.org/dyn/icsc/showcard.display?p\\_card\\_id=0472&p\\_version=2&p\\_lang=en](https://www.ilo.org/dyn/icsc/showcard.display?p_card_id=0472&p_version=2&p_lang=en). [Last accessed on 2024 Aug 15].
44. Sudakin DL. Occupational exposure to aluminium phosphide and phosphine gas? A suspected case report and review of the literature. *Hum Exp Toxicol* 2005;24:27-33.
45. Srinivas R, Agarwal R, Jairam A, Sakhuja V. Intravascular haemolysis due to glucose-6-phosphate dehydrogenase deficiency in a patient with aluminium phosphide poisoning. *Emerg Med J* 2007;24:67-8.
46. Vosooghi AA, Salmasi M. G6PD deficiency and aluminum phosphide poisoning. *J Res Med Sci* 2018;23:83.
47. Sanaei-Zadeh H. Aluminum phosphide poisoning and development of hemolysis and methemoglobinemia. *Indian J Crit Care Med* 2012;16:248-9.
48. The National Institute for Occupational Safety and Health (NIOSH). Phosphine; 2019. Available from: <https://www.cdc.gov/niosh/npg/npgd0505.html>. [Last accessed on 2024 Aug 11].
49. Darbari A, Tandon S, Chaudhary S, Bharadwaj M, Kumar A, Singh GP. Esophageal injuries due to aluminum phosphide tablet poisoning in India. *Asian Cardiovasc Thorac Ann* 2008;16:298-300.
50. Bhargava S, Rastogi R, Agarwal A, Jindal G. Esophagobronchial fistula – A rare complication of aluminum phosphide poisoning. *Ann Thorac Med* 2011;6:41-2.
51. Kargar A, Noroozian M, Ramezani M, Shadnia S, Mostafazadeh B, Erfan Talab Evini P, *et al.* Visual impairment following aluminum phosphide poisoning: A rare case. *Clin Case Rep* 2023;11:e7422.
52. International Agency for Research on Cancer (IARC). IARC Monographs on the Identification of Carcinogenic Hazards to Humans; 2016. Available from: <https://monographs.iarc.who>.



- int/list-of-classifications. [Last accessed on 2024 May 12].
53. United States Environmental Protection Agency (EPA). Phosphine; 2016. <https://www.epa.gov/sites/default/files/2016-09/documents/phosphine.pdf>. [Last accessed on 2024 Aug 11]
  54. Abdollahi M, Mehrpour O. Aluminum phosphide. In: Encyclopedia of Toxicology. London, England:Elsevier; 2014. p. 164-6.
  55. Abd-Allah M, Abdalla A, Mohamed N, Rady M, Farrag A, Salama K, *et al*. Updates on toxicology of aluminum phosphide and different management protocols. *Zagazig Univ Med J* 2022;28:1176-83. [doi: 10.21608/zumj.2022.125913.2491].
  56. UK Health Security Agency (UKHSA). Phosphine – Toxicological Overview; 2024. Available from: <https://www.gov.uk/government/publications/phosphine-properties-incident-management-and-toxicology/phosphine-toxicological-overview>. [Last accessed on 2024 Oct 09].
  57. Chugh SN, Ram S, Chugh K, Malhotra KC. Spot diagnosis of aluminium phosphide ingestion: An application of a simple test. *J Assoc Physicians India* 1989;37:219-20.
  58. Bumbrah GS, Krishan K, Kanchan T, Sharma M, Sodhi GS. Phosphide poisoning: A review of literature. *Forensic Sci Int* 2012;214:1-6.
  59. Leesch JG. Accuracy of different sampling pumps and detector tube combinations to determine phosphine concentrations1. *J Econ Entomol* 1982;75:899-905.
  60. Katwal S, Malbul K, Mandal SK, Kc S, Alam MZ, Karki P, *et al*. Successfully managed aluminum phosphide poisoning: A case report. *Ann Med Surg (Lond)* 2021;70:102868.
  61. Akkaoui M, Achour S, Abidi K, Himdi B, Madani A, Zeggwagh AA, *et al*. Reversible myocardial injury associated with aluminum phosphide poisoning. *Clin Toxicol (Phila)* 2007;45:728-31.
  62. Kalawat S, Thakur V, Thakur A, Punjabi N. Cardiovascular profile of aluminium phosphide poisoning and its clinical significance. *Int J Adv Med* 2016;3:859-64.
  63. Soltaninejad K, Beyranvand MR, Momenzadeh SA, Shadnia S. Electrocardiographic findings and cardiac manifestations in acute aluminum phosphide poisoning. *J Forensic Leg Med* 2012;19:291-3.
  64. Petrovic M, Otero D, Leigh A, Singh V. Acute heart failure due to aluminum phosphide poisoning. *Methodist Deakey Cardiovasc J* 2021;17:6-12.
  65. Hassanian-Moghaddam H, Shahnazi M, Zamani N, Bahrami-Motlagh H. Abdominal imaging in zinc phosphide poisoning. *Emerg Radiol* 2014;21:329-31.
  66. Hassanian-Moghaddam H, Shahnazi M, Zamani N, Rahimi M, Bahrami-Motlagh H, Amir H. Plain abdominal radiography: A powerful tool to prognosticate outcome in patients with zinc phosphide poisoning. *Clin Radiol* 2014;69:1062-5.
  67. Resuscitation Council UK Guidelines 2021. The ABCDE Approach; 2021. Available from: <https://www.resus.org.uk/library/abcde-approach#:~:text=Use%20the%20Airway%2C%20Breathing%2C%20Circulation,Assess%20the%20effects%20of%20treatment.> [Last accessed on 2024 Oct 09].
  68. Nasri Nasrabadi Z, Marashi SM. Comments on a systematic review of aluminium phosphide poisoning. *Arch Ind Hyg Toxicol* 2012;63:551.
  69. Helal NE, Lashin HI, Nagy AA, Shama MA, Mostafa TA, Wahdan AA. Potential role of paraffin oil gastric lavage in acute aluminum phosphide poisoning: A randomized controlled trial. *Environ Sci Pollut Res Int* 2022;29:33844-55.
  70. Hafez AS, Elgazzar FM, Sobh ZK, El-Ebiary AA. Gastrointestinal decontamination using oil-based solutions in patients with acute aluminum phosphide poisoning: A systematic review and meta-analysis. *Crit Rev Toxicol* 2024;54:235-51.
  71. Marashi SM, Majidi M, Raji Asadabadi H, Nasri-Nasrabadi Z. A common misconception in the management of aluminium phosphide poisoning. *Arch Ind Hyg Toxicol* 2013;64:475-6.
  72. Sanaei-Zadeh H, Marashi SM. Gastric decontamination in aluminium phosphide poisoning: A case against the use of water-based solutions. *Arch Ind Hyg Toxicol* 2016;67:364-5.
  73. Naddafi M, Mehrizi AA, Eghbal MA, Khansari MG, Azarmi Y, Sattari MR, *et al*. Reducing the risk of death induced by aluminum phosphide poisoning: The new therapies. *Chemosphere* 2022;294:133800.
  74. Agrawal VK, Bansal A, Singh RK, Kumawat BL, Mahajan P. Aluminum phosphide poisoning: Possible role of supportive measures in the absence of specific antidote. *Indian J Crit Care Med* 2015;19:109-12.
  75. Shaker HO, Rageh OE, Alnajjar M, Alshamaly NF, Abdelmaged WA, Abd-ElGawad M. Efficacy of intravenous N acetylcysteine as an adjuvant therapy in the treatment of acute aluminum phosphide poisoning: A systematic review and meta-analysis. *BMC Pharmacol Toxicol* 2023;24:59.
  76. Oghabian Z, Mehrpour O. Treatment of aluminium phosphide poisoning with a combination of intravenous glucagon, digoxin and antioxidant agents. *Sultan Qaboos Univ Med J* 2016;16:e352-5.
  77. Halvaei Z, Tehrani H, Soltaninejad K, Abdollahi M, Shadnia S. Vitamin E as a novel therapy in the treatment of acute aluminum phosphide poisoning. *Turk J Med Sci* 2017;47:795-800.
  78. Asghari MH, Abdollahi M, de Oliveira MR, Nabavi SM. A review of the protective role of melatonin during phosphine-induced cardiotoxicity: Focus on mitochondrial dysfunction, oxidative stress and apoptosis. *J Pharm Pharmacol* 2017;69:236-43.
  79. Hooshangi Shayesteh MR, Hani Z, Chamanara M, Parvizi MR, Golaghaei A, Nassireslami E. Evaluation of the protective effect of coenzyme Q(10) on hepatotoxicity caused by acute phosphine poisoning. *Int J Immunopathol Pharmacol* 2024;38:1-13.
  80. Sabir DK, Al-Masri A, Aldayel MF, Sharaf AA. Modulating oxidative stress, apoptosis, and mitochondrial dysfunctions on cardiotoxicity induced by aluminum phosphide pesticide using resveratrol. *Toxicol Mech Methods* 2024;34:727-35.
  81. Yang Y, Bustani GS, Alawsi T, Altalbawy FM, Kareem AK, Gupta J, *et al*. The cardioprotective effects of cerium oxide nanoparticles against the poisoning generated by aluminum phosphide pesticide: Controlling oxidative stress and mitochondrial damage. *Pestic Biochem Physiol* 2023;197:105701.
  82. Shabani M, Khezri S, Salimi A. Mitotherapy with fresh isolated cardiac mitochondria via injection into blood reduces aluminum phosphide-induced mortality and protects cardiac tissue against oxidative stress and mitochondrial damages. *Cardiovasc Toxicol* 2024;24:929-41.
  83. Baruah U, Sahni A, Sachdeva HC. Successful management of aluminium phosphide poisoning using intravenous lipid emulsion: Report of two cases. *Indian J Crit Care Med* 2015;19:735-8.
  84. Gheat HS, Fayed MM, Elgazzar FM, Draz EI, El-Kelany RS. The possible therapeutic role of intravenous lipid emulsion in acute aluminium phosphide poisoning: A randomized controlled clinical trial. *Toxicol Res (Camb)* 2024;13:tfae090.
  85. Shadnia S, Rahimi M, Pajoumand A, Rasouli MH, Abdollahi M. Successful treatment of acute aluminium phosphide poisoning: Possible benefit of coconut oil. *Hum Exp Toxicol* 2005;24:215-8.
  86. Ouaz M, Masmoudi S, Attia H, Dahmeni A, Salem AB, Majdoub A. Place of early renal replacement therapy in acute aluminum phosphide poisoning about one case. *Acta Sci Clin Case Rep* 2021;2:20-2.
  87. Chopra JS, Kalra OP, Malik VS, Sharma R, Chandna A. Aluminium phosphide poisoning: A prospective study of 16 cases in one year. *Postgrad Med J* 1986;62:1113-5.
  88. Hájek M, Chmelař D, Tlapák J, Rybárová V, Ondra P, Halouzka V. Accidental aluminum phosphide intoxication successfully treated with hyperbaric oxygen therapy: A case report. *Toxics*



- 2024;12:272.
89. Chacko J, Shivaprasad C. Fatal aluminium phosphide poisoning due to myocardial depression refractory to high dose inotropic support and intra-aortic balloon counterpulsation. *Indian J Crit Care Med* 2008;12:37-8.
  90. Siddaiah L, Adhyapak S, Jaydev S, Shetty G, Varghese K, Patil C, *et al.* Intra-aortic balloon pump in toxic myocarditis due to aluminum phosphide poisoning. *J Med Toxicol* 2009;5:80-3.
  91. Kumar A, Prakash J, Arya G, Anand Kumar Y, Aman D. Veno-arterial extracorporeal membrane oxygenation as a bridge to recovery in acute aluminium phosphide poisoning: A case report. *Asian J Med Sci* 2022;13:175-7.
  92. Nasa P, Gupta A, Mangal K, Nagrani SK, Raina S, Yadav R. Use of continuous renal replacement therapy in acute aluminum phosphide poisoning: A novel therapy. *Ren Fail* 2013;35:1170-2.
  93. Adel B, Elgharbawy NM, Shahin MM, Abo-Elfadl AA, Saad KM. Insulin-euglycemia therapy in acute aluminum phosphide poisoning: A randomized clinical trial. *Clin Toxicol (Phila)* 2023;61:1032-9.
  94. Ullah A, Jan S, Shahzad H, Dar MR, Khan S, Ahmad K, *et al.* Therapeutic effect of glucose-insulin-potassium (GIK) infusion therapy in the treatment of acute aluminum phosphide poisoning: An institutional study. *Cureus* 2024;16:e76182.
  95. Niknahad H, Heidari R, Jangjou A, Asghari V, Niknahad FM, Goudarzi F, *et al.* The therapeutic effect of a novel parenteral formulation of dihydroxyacetone in aluminum phosphide-intoxicated patients. *Heliyon* 2023;9:e22165.
  96. Sobh ZK, Ghanem M, Kholief M. Physicians' perspectives on different therapeutic approaches for aluminum phosphide poisoning and their relevant outcomes. *Toxicol Res (Camb)* 2023;12:615-25.
  97. Asrie AB, Atnafie SA, Getahun KA, Birru EM, Mekonnen GB, Alemayehu GA, *et al.* Poisoning cases and their management in Amhara National Regional State, Ethiopia: Hospital-based prospective study. *PLoS One* 2024;19:e0303438.
  98. Saleh A, Makhlof M. Outcome of toxicity and mortality predictors of aluminum phosphide poisoning in Fayoum Governorate, Egypt. *Zagazig J Forensic Med* 2018;16:40-52.
  99. Elsayed EA, Eweda SA, El-Morsy SA. Assessment of the role of N-terminal pro-B-type natriuretic peptide as a predictive biomarker of mortality in acute aluminum phosphide poisoning. *Biomarkers* 2024;29:376-83.
  100. Chugh SN, Pal R, Singh V, Seth S. Serial blood phosphine levels in acute aluminium phosphide poisoning. *J Assoc Physicians India* 1996;44:184-5.
  101. Mehrpour O, Singh S. Rice tablet poisoning: A major concern in Iranian population. *Hum Exp Toxicol* 2010;29:701-2.
  102. Rizwanullah, Salcedo YE, Mukesh Mehta J, Al Balushi J, Khariwal M, Patel N. Exploring the protective role of G6PD deficiency in aluminum phosphide poisoning: A case report and review of the literature. *Cureus* 2024;16:e58888.
  103. Ghonem MM, Abdelnoor AA, Hodeib AA. Shock and modified shock indices in predicting poisoning severity and outcomes in acute aluminum phosphide poisoned patients. *Toxicol Res (Camb)* 2024;13:tfad124.
  104. Berck B, Gunther FA. Rapid determination of sorption affinity of phosphine by fumigation within a gas chromatographic column. *J Agric Food Chem* 1970;18:148-53.
  105. Eismann F, Glindemann D, Bergmann A, Kusch P. Soils as source and sink of phosphine. *Chemosphere* 1997;35:523-33.
  106. Hilton HW, Robison WH. Fate of zinc phosphide and phosphine in the soil – Water environment. *J Agric Food Chem* 1972;20:1209-13.
  107. United States Department of Agriculture (USDA). The Use of Aluminum Phosphide in Wildlife Damage Management; 2020. [https://www.aphis.usda.gov/wildlife\\_damage/nepa/risk\\_assessment/9-aluminum-phosphide.pdf](https://www.aphis.usda.gov/wildlife_damage/nepa/risk_assessment/9-aluminum-phosphide.pdf). [Last accessed on 2024 Sep 01].
  108. Occupational Safety and Health Administration (OSHA). Occupational Safety and Health Standards; 2016. Available from: <https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.132>. [Last accessed on 2024 Oct 03].